DAPA & AbbVie – Women’s Health Sessions – Session 1 – Wednesday, June 23


  • June 23, 2021
    6:00 pm - 7:00 pm

  WEBINAR 1: Wednesday, June 23, 2021 – 6PM CT  Endometriosis and Elagolix, indicated for moderate to severe endometriosis pain. One of the most common gynecologic disorders in the U.S., and affecting  roughly 10% (190 million) of reproductive age women and girls worldwide, endometriosis is a highly estrogen-dependent, chronic, inflammatory disease characterized by the growth Read moreDAPA & AbbVie – Women’s Health Sessions – Session 1 – Wednesday, June 23

DAPA & AbbVie – Women’s Health Sessions – Session 2 – Thursday, June 24


  • June 24, 2021
    6:00 pm - 7:00 pm

WEBINAR 2: Thursday, June 24 – 6PM CT UTERINE FIBROIDS & Elagolix+Estradiol/NETA, indicated for heavy menstrual bleeding associated with uterine leiomyomas in pre-menopausal women Uterine fibroids, also called leiomyomas, are estrogen and progesterone-dependent non-cancerous tumors of the uterus and are the most common type of benign tumor in women of reproductive age. Traditionally, uterine fibroids Read moreDAPA & AbbVie – Women’s Health Sessions – Session 2 – Thursday, June 24